Broun E R, Iseminger K A, Bookman M
Bone Marrow Transplant Unit, Indiana University School of Medicine, Indianapolis.
Am J Clin Oncol. 1995 Apr;18(2):164-6. doi: 10.1097/00000421-199504000-00015.
Twenty-two patients with recurrent ovarian cancer were entered into a Phase II trial of edatrexate at a dose of 80 mg/m2 i.v. weekly for five consecutive weeks. One patient received an inadequate trial, and six did not complete one cycle due to adverse effects. There were 21 patients evaluable for toxicity and 15 for response. There were no objective responses, 10/15 (67%) had stable disease, 5/15 (33%) increasing disease. Toxicity was predominantly stomatitis and hematologic. Two patients developed skin rashes, and one experienced pulmonary toxicity felt to be related to the drug. Edatrexate administered in this dose and schedule has no demonstrated activity, but moderately severe toxicity in patients with previously treated advanced ovarian cancer.
22例复发性卵巢癌患者进入了一项乙磺叶酸的II期试验，剂量为80mg/m²，静脉注射，每周一次，连续五周。1例患者接受的试验不充分，6例因不良反应未完成一个周期。有21例患者可评估毒性，15例可评估疗效。无客观缓解，15例中有10例（67%）病情稳定，5例（33%）病情进展。毒性主要为口腔炎和血液学毒性。2例患者出现皮疹，1例出现与药物相关的肺部毒性。以该剂量和方案给药的乙磺叶酸未显示出活性，但在先前接受过治疗的晚期卵巢癌患者中存在中度严重毒性。
